Loring Wolcott & Coolidge Fiduciary Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-500	Closed	-$1K	–	754
2018 Q3	$1K	Hold	500	–	–	﹤0.01%	649
2018 Q2	$1K	Hold	500	–	–	﹤0.01%	664
2018 Q1	$1K	Hold	500	–	–	﹤0.01%	718
2017 Q4	$1K	Hold	500	–	–	﹤0.01%	732
2017 Q3	$2K	Hold	500	–	–	﹤0.01%	688
2017 Q2	$1K	Hold	500	–	–	﹤0.01%	636
2017 Q1	$1K	Hold	500	–	–	﹤0.01%	611
2016 Q4	$1K	Hold	500	–	–	﹤0.01%	592
2016 Q3	$2K	Hold	500	–	–	﹤0.01%	602
2016 Q2	$2K	Hold	500	–	–	﹤0.01%	626
2016 Q1	$2K	Hold	500	–	–	﹤0.01%	606
2015 Q4	$2K	Hold	500	–	–	﹤0.01%	630
2015 Q3	$3K	Hold	500	–	–	﹤0.01%	597
2015 Q2	$3K	Hold	500	–	–	﹤0.01%	597
2015 Q1	$4K	Hold	500	–	–	﹤0.01%	601
2014 Q4	$4K	Hold	500	–	–	﹤0.01%	605
2014 Q3	$4K	Hold	500	–	–	﹤0.01%	576
2014 Q2	$5K	Hold	500	–	–	﹤0.01%	593
2014 Q1	$4K	Hold	500	–	–	﹤0.01%	597
2013 Q4	$4K	Hold	500	–	–	﹤0.01%	569
2013 Q3	$4K	Hold	500	–	–	﹤0.01%	532
2013 Q2	$4K	Buy	+500	New	+$3.9K	﹤0.01%	577

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's PDLI Position: Q4 2018 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2018, closing a stake of 500 shares — an estimated $1K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in PDLI in Q2 2013 and held it in 22 quarters. The position peaked at $5K in Q2 2014. 154 funds tracked by Wall St. Rank hold PDLI as of Q4 2018.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2018 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 500 PDL BioPharma, Inc. shares in Q4 2018, an estimated $1K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 22 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's PDL BioPharma, Inc. position peaked at $5K in Q2 2014.
154 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2018.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.